Physician

James Schley Ashford, M.D.

According to 2025 Medicare claims, James Ashford, M.D. (NPI: 1447693833) practices pain management in the Athens-Clarke County, GA market, with the plurality of this provider's patient population coming from Clarke, GA. This provider's primary affiliated billing organization is ASHFORD PAIN SOLUTIONS, LLC (NPI: 1689178170; TIN: 824863664) and primary practice location at 30606-2168.

Ashford's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 298 traditional Medicare patients, billed 6,822 HCPCS/CPT codes, and received $410,531 in Medicare payments. The top billing code was G0482 (Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms). Part D data shows 16,202 prescription claims across 1,205 beneficiaries totaling $986,765 in drug costs, led by Belbuca (Buprenorphine Hcl). 2022 DME data shows 17 claims. Open Payments data shows 24 records totaling $574. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $41,118 to $410,531. Similarly, Part D prescription costs have moved sharply higher in recent years, from $49,303 to $986,765. In contrast, DME billing represents a smaller volume and changed little.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	56	582	$41,118
2019	128	15,301	$197,394
2020	183	50,453	$274,374
2021	302	33,704	$226,989
2022	320	39,283	$477,904
2023	329	10,352	$477,384
2024	298	6,822	$410,531

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	101	630	$49,303
2019	205	3,170	$363,647
2020	333	5,744	$849,661
2021	793	7,896	$1,120,822
2022	1,024	19,253	$1,954,720
2023	1,208	23,420	$1,693,471
2024	1,205	16,202	$986,765

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	17	17	$13,267
2019	32	32	$25,535
2020	48	63	$46,685
2021	16	16	$12,643
2022	17	17	$13,333
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms	126	290	$193
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms	168	485	$153
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	270	1,926	$61
99490	Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month	111	824	$45
80305	Testing for presence of drug, read by direct observation	266	878	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Belbuca	Buprenorphine Hcl	188	5,610	$142,326
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	3,401	93,220	$107,301
Buprenorphine	Buprenorphine	385	10,769	$101,403
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	3,001	81,991	$76,962
Xtampza Er	Oxycodone Myristate	189	5,030	$64,143

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	24	$574	SCILEX PHARMACEUTICALS INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for James Schley Ashford, M.D.?

Tedicare shows public-source Medicare data for James Schley Ashford, M.D. (NPI 1447693833), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does James Schley Ashford, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to James Schley Ashford, M.D.?

James Schley Ashford, M.D. is linked to ASHFORD PAIN SOLUTIONS, LLC (billing NPI 1689178170) in the available physician profile data.

Does James Schley Ashford, M.D. have Open Payments data?

James Schley Ashford, M.D. has 24 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.